Works matching DE "TAKEDA Pharmaceutical Co. Ltd."
1
- Sleep & Biological Rhythms, 2004, v. 2, p. S3, doi. 10.1111/j.1479-8425.2004.00084.x
- Article
2
- Formulary, 2008, v. 43, n. 6, p. 188
- Article
3
- Formulary, 2006, v. 41, n. 12, p. 671
- Article
5
- Formulary, 2005, v. 40, n. 11, p. 382
- Article
9
- Applied Medical Informatics, 2010, v. 26, n. 1/2, p. 42
- Morogvan, Claudiu;
- Cosma, Smaranda;
- Ghibu, Steliana;
- Văleanu, Mădălina A.
- Article
10
- Expert Review of Clinical Pharmacology, 2011, v. 4, n. 4, p. 415
- Article
11
- Clinical Infectious Diseases, 2017, v. 65, n. 1, p. ii
- Article
12
- AIDS Patient Care & STDs, 2005, v. 19, n. 5, p. 350, doi. 10.1089/apc.2005.19.350
- Article
13
- Chemistry & Industry, 2015, v. 79, n. 10, p. 19, doi. 10.1002/cind.7910_5.x
- Article
14
- BioEssays, 2010, v. 32, n. 6, p. A3
- Article
15
- TCE: The Chemical Engineer, 2018, n. 924, p. 17
- Article
16
- TCE: The Chemical Engineer, 2018, n. 923, p. 19
- Article
17
- TCE: The Chemical Engineer, 2014, n. 875, p. 6
- Article
18
- TCE: The Chemical Engineer, 2011, n. 841, p. 9
- Article
19
- TCE: The Chemical Engineer, 2008, n. 803, p. 8
- Article
20
- Nature Medicine, 2011, v. 17, n. 10, p. 1171, doi. 10.1038/nm1011-1171a
- Article
21
- Nature Medicine, 2010, v. 16, n. 6, p. 614, doi. 10.1038/nm0610-614a
- Article
22
- Bio-IT World, 2005, v. 4, n. 3, p. 12
- Article
23
- Nature Reviews Drug Discovery, 2014, v. 13, n. 7, p. 485, doi. 10.1038/nrd4388
- Article
24
- Nature Reviews Drug Discovery, 2014, v. 13, n. 2, p. 91, doi. 10.1038/nrd4246
- Article
25
- Nature Reviews Drug Discovery, 2013, v. 12, n. 9, p. 658, doi. 10.1038/nrd4110
- Article
27
- Nature Reviews Drug Discovery, 2008, v. 7, n. 5, p. 378, doi. 10.1038/nrd2585
- Article
28
- Nature Reviews Drug Discovery, 2008, v. 7, n. 3, p. 192, doi. 10.1038/nrd2547
- Article
29
- Nature Reviews Drug Discovery, 2005, v. 4, n. 11, p. 876, doi. 10.1038/nrd1890
- Article
30
- British Journal of Community Nursing, 2006, v. 11, n. 11, p. 498
- Article
32
- Applied Clinical Trials, 2018, v. 27, n. 6, p. 13
- Article
33
- Applied Clinical Trials, 2005, v. 14, n. 9, p. 70
- Article
34
- Nature Biotechnology, 2015, v. 33, n. 6, p. 573, doi. 10.1038/nbt0615-573c
- Article
35
- Nature Biotechnology, 2014, v. 32, n. 11, p. 1070, doi. 10.1038/nbt1114-1070a
- Article
36
- Nature Biotechnology, 2013, v. 31, n. 8, p. 667, doi. 10.1038/nbt0813-667
- Article
37
- Nature Biotechnology, 2013, v. 31, n. 4, p. 270, doi. 10.1038/nbt0413-270a
- Article
38
- American Journal of Health-System Pharmacy, 2009, v. 66, n. 7, p. 606, doi. 10.2146/news090028
- Article
39
- Expert Review of Cardiovascular Therapy, 2011, v. 9, n. 7, p. 811
- Article
41
- Chemistry & Industry, 2012, v. 76, n. 9, p. 46, doi. 10.1002/cind.7609_13.x
- Article
42
- Chemistry & Industry, 2009, n. 15, p. 13
- Article
43
- Chemistry & Industry, 2008, n. 16, p. 7
- Article
44
- Chemistry & Industry, 2008, n. 11, p. 15
- Article
45
- Chemistry & Industry, 2007, n. 16, p. 10
- Article
46
- Chemistry & Industry, 2006, n. 3, p. 12
- Article
47
- Nature, 2008, v. 452, n. 7186, p. 399, doi. 10.1038/452399c
- Article
48
- Indian Practitioner, 2019, v. 72, n. 11, p. 48
- Article
49
- Vaccines, 2020, v. 8, n. 4, p. 674, doi. 10.3390/vaccines8040674
- Aguiar, Maíra;
- Stollenwerk, Nico
- Article
50
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 1, p. 97, doi. 10.1111/j.1463-1326.2011.01541.x
- Article